ATE484295T1 - Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen - Google Patents

Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Info

Publication number
ATE484295T1
ATE484295T1 AT06117838T AT06117838T ATE484295T1 AT E484295 T1 ATE484295 T1 AT E484295T1 AT 06117838 T AT06117838 T AT 06117838T AT 06117838 T AT06117838 T AT 06117838T AT E484295 T1 ATE484295 T1 AT E484295T1
Authority
AT
Austria
Prior art keywords
orally administered
increasing
bioavailability
preparations
pharmaceutical compounds
Prior art date
Application number
AT06117838T
Other languages
English (en)
Inventor
Johannes Henricus Matthias Schellens
Alfred Hermanus Schinkel
Original Assignee
Cancer Res Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Ventures Ltd filed Critical Cancer Res Ventures Ltd
Application granted granted Critical
Publication of ATE484295T1 publication Critical patent/ATE484295T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06117838T 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen ATE484295T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30

Publications (1)

Publication Number Publication Date
ATE484295T1 true ATE484295T1 (de) 2010-10-15

Family

ID=26642978

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
AT00931720T ATE337016T1 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00931720T ATE337016T1 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Country Status (10)

Country Link
US (2) US7030132B2 (de)
EP (2) EP1749540B1 (de)
AT (2) ATE484295T1 (de)
AU (1) AU4955200A (de)
CY (1) CY1105795T1 (de)
DE (2) DE60030283T2 (de)
DK (1) DK1189637T3 (de)
ES (1) ES2270834T3 (de)
PT (1) PT1189637E (de)
WO (1) WO2000069390A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1749540B1 (de) * 1999-05-17 2010-10-13 Cancer Research Ventures Limited Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
RU2007103703A (ru) * 2004-07-01 2008-08-10 Дзе Недзеландз Кэнсе Инститьют (Nl) Комбинация, включающая ингибитор бррм (белка резистентности рака молочной железы) и 4-(4-метилпиперазин-1-илметил)-n-(4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил)-бензамид
CN101010114B (zh) 2004-08-27 2010-05-26 皇家飞利浦电子股份有限公司 电子遥控药丸和用于供应至少一种药物的***
JP2008521794A (ja) * 2004-11-29 2008-06-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 少なくとも一の薬剤を輸送するための、少なくとも一のセンサを有する電子制御式の錠剤およびシステム
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
CN101945613B (zh) * 2008-02-18 2014-08-13 皇家飞利浦电子股份有限公司 为患者用药
JP5681861B2 (ja) * 2008-03-31 2015-03-11 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ センサを有する嚥下型カプセルを作成する方法
JP5627569B2 (ja) 2008-04-30 2014-11-19 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドＳｉｅｍｅｎｓ Ｍｅｄｉｃａｌ Ｓｏｌｕｔｉｏｎｓ ＵＳＡ，Ｉｎｃ． 新規基質に基づくｐｅｔ造影剤
CN102065930B (zh) * 2008-06-19 2013-05-22 皇家飞利浦电子股份有限公司 用于在潮湿环境下传递粉末状药物的装置
CN102076375B (zh) * 2008-06-25 2013-11-20 皇家飞利浦电子股份有限公司 包括多个药物储存器的电子药丸
US10046109B2 (en) 2009-08-12 2018-08-14 Progenity, Inc. Drug delivery device with compressible drug reservoir
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
CZ283038B6 (cs) 1991-01-11 1997-12-17 Laboratoires Glaxo Sa Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
WO1994001408A1 (en) 1992-07-10 1994-01-20 Laboratoires Glaxo S.A. Anilide derivatives
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
BR9509251A (pt) 1994-10-05 1997-10-21 Glaxo Wellcome Inc Composição farmacêutica processo de reverte reduzir ou inibir a resistência a multidrogas ou de restaurar a sensibilidade de um tumor e artigo manufaturado
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
BR9809694A (pt) 1997-05-27 2000-10-03 Baker Norton Pharma Processo e composição para administração de taxanos oralmente a pacientes humanos
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE69935782T3 (de) * 1998-02-05 2017-01-05 University Of Maryland, Baltimore Brustkrebsresistenzprotein (BCRP) und für dieses kodierende DNA
AU764370B2 (en) 1998-06-18 2003-08-14 George Washington University, The Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
DK1102594T3 (da) 1998-08-05 2002-08-26 Aventis Pharma Sa Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
EP1749540B1 (de) * 1999-05-17 2010-10-13 Cancer Research Ventures Limited Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
DE60045114D1 (de) 2010-11-25
EP1749540A3 (de) 2007-05-30
EP1189637A2 (de) 2002-03-27
DE60030283D1 (de) 2006-10-05
ATE337016T1 (de) 2006-09-15
WO2000069390A3 (en) 2001-12-13
US7030132B2 (en) 2006-04-18
CY1105795T1 (el) 2011-02-02
US20060128743A1 (en) 2006-06-15
AU4955200A (en) 2000-12-05
EP1749540A2 (de) 2007-02-07
EP1749540B1 (de) 2010-10-13
DK1189637T3 (da) 2006-12-11
DE60030283T2 (de) 2007-09-20
EP1189637B1 (de) 2006-08-23
PT1189637E (pt) 2007-01-31
ES2270834T3 (es) 2007-04-16
WO2000069390A2 (en) 2000-11-23
US20020128282A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ATE484295T1 (de) Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
DE69526428T2 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
DK0794794T3 (da) Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
ATE448782T1 (de) Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
ATE292453T1 (de) Antivirale arznei
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
SE8100276L (sv) Farmaceutiskt aktiv komposition omfattande ketoner och heterocykliska foreningar
EE200300371A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kopmositsioonid
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
SE9902742D0 (sv) New pharmaceutical formultion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties